Regulus Therapeutics. has been granted a patent for compositions and methods that inhibit miR-122 activity, featuring specific nucleoside modifications for enhanced potency and liver delivery. These compositions are intended for treating hepatitis C virus infections and related conditions. GlobalData’s report on Regulus Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Regulus Therapeutics, siRNA gene silencing was a key innovation area identified from patents. Regulus Therapeutics's grant share as of June 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Inhibitors of mir-122 for hepatitis c treatment
The granted patent US12005120B2 outlines a novel compound and its applications in treating hepatitis C virus (HCV) infections. The primary claim describes a specific chemical structure, with subsequent claims detailing variations such as pharmaceutically acceptable salts, including sodium salts. The patent also covers pharmaceutical compositions that incorporate the compound, either in aqueous solutions or as lyophilized formulations. Notably, the compositions can consist essentially of the compound in saline solutions, which may enhance the compound's stability and efficacy in therapeutic applications.
The patent further delineates methods for inhibiting the activity of miR-122 in cells and treating HCV infections. It specifies administration protocols for the compound, either alone or in conjunction with direct-acting antivirals (DAAs), over treatment periods of up to 12 weeks. The claims encompass various HCV genotypes and patient conditions, including treatment-naïve subjects and those with HCV-associated diseases or co-infections. The patent also addresses dosing parameters, indicating that effective doses may be as low as 0.5 mg/kg, thereby suggesting a potential for reduced side effects while maintaining therapeutic efficacy. Overall, the patent presents a comprehensive approach to HCV treatment, emphasizing both the compound's chemical properties and its clinical applications.
To know more about GlobalData’s detailed insights on Regulus Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
